Ekaterina Smirnyagina

We want to solve immune dysfunction. Many cancers and other diseases are caused, or resist treatment, because T cells cant recognize or target cells correctly.​ Were progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system.​ This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.

Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another targeting cone-rod dystrophy (CRD), an inherited retinal disease. Lead development candidate AGTC-501, is a gene therapy program in Phase II clinical trials for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss in boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP, including both rod and cone loss. Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space. The Company is supported by funds from Syncona, Forbion, Oxford Science Enterprises, TCGX, Advent Life Sciences and additional investors.

See protein, DNA and RNA molecules that make life work, in nanoparticles, viruses, bacteria, cells and tissue. We believe that understanding science at a molecular level will fundamentally allow you to unlock new discoveries, so we created our flagship product, The Nanoimager. We built the worlds first desktop compatible compact super-resolution microscope, but we did it our way. Our teams have a restless enthusiasm to bring technologies like super-resolution to a new community of researchers and we continue working until barriers of accessibility and affordability are addressed. Our mission is to ensure research and collaboration tools are available to those willing to ask why or how things are the way they are and answer questions never asked before. We can’t wait to see and hear about what new questions you will ask!

Our mission at MiroBio is to deliver transformational immunotherapies for people suffering from autoimmune disease. Immune imbalance is at the heart of many conditions which are marked by an attack on the body’s own cells. MiroBio is advancing a new class of therapies designed to restore immune balance – or homeostasis – and potentially provide durable remission from these chronic, complex conditions. To achieve this, MiroBio has built deep expertise in an emerging area of immunology: precise activation of inhibitory pathways to restore healthy immune function. Our pipeline of agonistic antibodies and supporting platform are informed by over a decade of foundational research. MiroBio draws upon a transatlantic team of advisers, drug developers and leading healthcare investors to further its leadership in this vast new area of immunology.

SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases. SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. The company’s current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for this year.

Veracyte is a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. We provide novel insights, expertise and capabilities that empower our biopharmaceutical partners to confidently advance every step of their oncology drug development programs.

Confo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments. Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies, Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium. For more information: www.confotherapeutics.com

About iSTAR Medical iSTAR Medical is committed to delivering breakthrough eye care solutions. Our most advanced product, MINIject, is approved in Europe for the treatment of open-angle glaucoma – the leading cause of irreversible blindness[1] – and we are aiming to seek market approval in the US. We believe MINIject’s unique tissue-integrating capabilities unlock a safer, and more effective option for patients. We are building an exceptional team and pipeline of best-in-class products such as MINIject to establish new treatment paradigms in eye care conditions with the highest patient needs. About MINIject® MINIject is iSTAR Medical’s innovative MIGS device for patients with primary open-angle glaucoma. MINIject combines the unique porous structure of its proprietary STAR material with the power offered by the supraciliary space. As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications. About Glaucoma Glaucoma is a progressive disease affecting over 100 million people globally, of which primary open-angle glaucoma is the most common form.[1][2] IOP reduction, through medication or surgery, helps delay disease progression.[3] MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile.[2] MINIject is potentially best-in-class for its promising long-term efficacy and safety. [1] Jonas JB, Aung T, Bourne RR et al. “Glaucoma”. Lancet 2017; 390: 2083–93 [2] Market Scope, “2021 Glaucoma Surgical Device Market Report”, July 2021. https://www.market-scope.com/pages/reports/267/2021-glaucoma-surgical-device-market-report [3] “European Glaucoma Society Terminology and Guidelines for Glaucoma”, 4th Edition: British Journal of Ophthalmology. 2017;101:1-195 https://bjo.bmj.com/content/101/5/73 MINIject is a registered trademark in the European Union.

"Innovative medicine for everyone, everywhere"​ Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia operates in the diabetes and metabolic disease field. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. For more information, visit our website: www.adocia.com For careers offers, please click to the following link : http://offres.adocia.com/en

When it comes to life-threatening diseases, we are one family. We at Kiadis are focusing our research & development on NK cell therapeutics, leveraging the natural strengths of our immune systems to source the best cells for life.

Ablynx, a Sanofi company, is engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in the treatment of a range of serious and life-threatening human diseases. Ablynx advances a portfolio of Nanobody-based therapeutic programs in several major disease areas, including inflammation, haematology, immuno-oncology and oncology. The acquisition of Ablynx (June 2018) continues Sanofi’s commitment to breakthrough innovation, focused on technologies addressing multiple disease targets with single multi-specific molecules. Sanofi is committed to accelerating Ablynx’s Nanobody development programmes.

We want to solve immune dysfunction. Many cancers and other diseases are caused, or resist treatment, because T cells cant recognize or target cells correctly.​ Were progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system.​ This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.

Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another targeting cone-rod dystrophy (CRD), an inherited retinal disease. Lead development candidate AGTC-501, is a gene therapy program in Phase II clinical trials for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss in boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP, including both rod and cone loss. Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space. The Company is supported by funds from Syncona, Forbion, Oxford Science Enterprises, TCGX, Advent Life Sciences and additional investors.

See protein, DNA and RNA molecules that make life work, in nanoparticles, viruses, bacteria, cells and tissue. We believe that understanding science at a molecular level will fundamentally allow you to unlock new discoveries, so we created our flagship product, The Nanoimager. We built the worlds first desktop compatible compact super-resolution microscope, but we did it our way. Our teams have a restless enthusiasm to bring technologies like super-resolution to a new community of researchers and we continue working until barriers of accessibility and affordability are addressed. Our mission is to ensure research and collaboration tools are available to those willing to ask why or how things are the way they are and answer questions never asked before. We can’t wait to see and hear about what new questions you will ask!

Our mission at MiroBio is to deliver transformational immunotherapies for people suffering from autoimmune disease. Immune imbalance is at the heart of many conditions which are marked by an attack on the body’s own cells. MiroBio is advancing a new class of therapies designed to restore immune balance – or homeostasis – and potentially provide durable remission from these chronic, complex conditions. To achieve this, MiroBio has built deep expertise in an emerging area of immunology: precise activation of inhibitory pathways to restore healthy immune function. Our pipeline of agonistic antibodies and supporting platform are informed by over a decade of foundational research. MiroBio draws upon a transatlantic team of advisers, drug developers and leading healthcare investors to further its leadership in this vast new area of immunology.

SpyBiotech is a UK-based company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases. SpyBiotech was spun out of the University of Oxford in 2017. Its proprietary protein superglue technology binds antigens to vaccine delivery platforms in a way which minimizes delivery risk and enhances immunogenicity and efficacy. The company’s current lead candidate is against human cytomegalovirus (HCMV), with clinical studies planned for this year.